IO Biotech (IOBT) Competitors $0.77 +0.01 (+1.42%) (As of 12:37 PM ET) Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrends IOBT vs. CRDF, CMPX, SLN, MGNX, ADCT, CYBN, CADL, INZY, PRQR, and OPTShould you be buying IO Biotech stock or one of its competitors? The main competitors of IO Biotech include Cardiff Oncology (CRDF), Compass Therapeutics (CMPX), Silence Therapeutics (SLN), MacroGenics (MGNX), ADC Therapeutics (ADCT), Cybin (CYBN), Candel Therapeutics (CADL), Inozyme Pharma (INZY), ProQR Therapeutics (PRQR), and Opthea (OPT). These companies are all part of the "pharmaceutical products" industry. IO Biotech vs. Cardiff Oncology Compass Therapeutics Silence Therapeutics MacroGenics ADC Therapeutics Cybin Candel Therapeutics Inozyme Pharma ProQR Therapeutics Opthea Cardiff Oncology (NASDAQ:CRDF) and IO Biotech (NASDAQ:IOBT) are both small-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their earnings, risk, institutional ownership, community ranking, dividends, profitability, valuation, media sentiment and analyst recommendations. Is CRDF or IOBT more profitable? IO Biotech has a net margin of 0.00% compared to Cardiff Oncology's net margin of -6,238.17%. Cardiff Oncology's return on equity of -73.97% beat IO Biotech's return on equity.Company Net Margins Return on Equity Return on Assets Cardiff Oncology-6,238.17% -73.97% -60.40% IO Biotech N/A -86.56%-75.24% Which has more risk and volatility, CRDF or IOBT? Cardiff Oncology has a beta of 1.89, indicating that its stock price is 89% more volatile than the S&P 500. Comparatively, IO Biotech has a beta of 0.27, indicating that its stock price is 73% less volatile than the S&P 500. Do institutionals & insiders have more ownership in CRDF or IOBT? 16.3% of Cardiff Oncology shares are owned by institutional investors. Comparatively, 54.8% of IO Biotech shares are owned by institutional investors. 7.6% of Cardiff Oncology shares are owned by insiders. Comparatively, 2.3% of IO Biotech shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth. Does the MarketBeat Community believe in CRDF or IOBT? Cardiff Oncology received 19 more outperform votes than IO Biotech when rated by MarketBeat users. However, 91.67% of users gave IO Biotech an outperform vote while only 64.06% of users gave Cardiff Oncology an outperform vote. CompanyUnderperformOutperformCardiff OncologyOutperform Votes4164.06% Underperform Votes2335.94% IO BiotechOutperform Votes2291.67% Underperform Votes28.33% Which has higher earnings & valuation, CRDF or IOBT? Cardiff Oncology has higher revenue and earnings than IO Biotech. Cardiff Oncology is trading at a lower price-to-earnings ratio than IO Biotech, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioCardiff Oncology$688K397.63-$41.44M-$0.94-5.69IO BiotechN/AN/A-$86.08M-$1.37-0.55 Does the media favor CRDF or IOBT? In the previous week, Cardiff Oncology had 15 more articles in the media than IO Biotech. MarketBeat recorded 16 mentions for Cardiff Oncology and 1 mentions for IO Biotech. IO Biotech's average media sentiment score of 1.44 beat Cardiff Oncology's score of 0.57 indicating that IO Biotech is being referred to more favorably in the news media. Company Overall Sentiment Cardiff Oncology Positive IO Biotech Positive Do analysts recommend CRDF or IOBT? Cardiff Oncology presently has a consensus target price of $10.33, indicating a potential upside of 93.15%. IO Biotech has a consensus target price of $9.33, indicating a potential upside of 1,129.36%. Given IO Biotech's higher probable upside, analysts plainly believe IO Biotech is more favorable than Cardiff Oncology.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Cardiff Oncology 0 Sell rating(s) 0 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 3.00IO Biotech 0 Sell rating(s) 0 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 3.00 SummaryCardiff Oncology beats IO Biotech on 9 of the 15 factors compared between the two stocks. Ad Wealthpin ProVacuum up cash with these special trades? Have you ever heard about a “volatility vacuum?” Most people haven’t. It all revolves around this formula right here. Now, the most important thing is that this equation — when applied to certain tickers at a certain time each month —- can trigger these “volatility vacuums.” And when that happens, anyone has the shot at sucking out payouts of $290, $350, even $1,350 in as little as 24 hours. (With just a $1k starting stake!) Granted, there were smaller wins and those that did not work out but best of all, we can know exactly when these opportunities will hit. I’ve used this info to create a Cash Calendar that lays out the precise dates of these payouts. And I’m sending it for FREE to anyone who joins me during my FREE training right here. Get IO Biotech News Delivered to You Automatically Sign up to receive the latest news and ratings for IOBT and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart IOBT vs. The Competition Export to ExcelMetricIO BiotechPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$50.02M$6.87B$5.19B$9.32BDividend YieldN/A3.06%4.78%4.06%P/E Ratio-0.5510.75128.2217.54Price / SalesN/A288.101,259.00139.66Price / CashN/A56.6541.2237.95Price / Book0.385.394.884.92Net Income-$86.08M$152.04M$119.69M$225.78M7 Day Performance-10.05%-4.33%16.64%-1.56%1 Month Performance-13.18%2.79%16.32%6.68%1 Year Performance-49.72%17.30%35.37%22.48% IO Biotech Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)IOBTIO Biotech3.5026 of 5 stars$0.77+1.4%$9.33+1,112.1%-46.3%$50.73MN/A-0.5630Positive NewsCRDFCardiff Oncology2.1616 of 5 stars$4.07+3.8%$10.33+153.9%+282.1%$208.10M$490,000.00-4.1720Short Interest ↑CMPXCompass Therapeutics2.7597 of 5 stars$1.48+1.4%$6.75+356.1%-3.8%$203.63M$850,000.00-4.0720Gap UpSLNSilence Therapeutics3.6694 of 5 stars$6.74+4.5%$57.20+748.7%-59.4%$201.73M$31.55M-4.11100MGNXMacroGenics3.8093 of 5 stars$3.21+0.3%$7.63+137.5%-63.9%$201.47M$139.77M-2.03430ADCTADC Therapeutics3.1915 of 5 stars$2.08+10.0%$8.00+284.8%+34.0%$201.02M$70.72M-0.86310CYBNCybin1.8676 of 5 stars$10.00+2.2%$138.00+1,280.0%N/A$199.92MN/A-1.4850CADLCandel Therapeutics2.5014 of 5 stars$6.07-10.1%$11.00+81.2%+392.5%$197.13M$120,000.00-3.6060Analyst ForecastHigh Trading VolumeINZYInozyme Pharma2.006 of 5 stars$3.05+0.7%$17.00+457.4%-26.9%$195.93MN/A-2.0850PRQRProQR Therapeutics2.3872 of 5 stars$2.39-15.5%$7.60+218.0%+36.7%$195.22M$7.05M-8.13180High Trading VolumeOPTOpthea2.2355 of 5 stars$3.34+2.8%$12.00+259.3%+29.8%$195.04M$124,666.000.008News CoveragePositive NewsGap Down Related Companies and Tools Related Companies Cardiff Oncology Competitors Compass Therapeutics Competitors Silence Therapeutics Competitors MacroGenics Competitors ADC Therapeutics Competitors Cybin Competitors Candel Therapeutics Competitors Inozyme Pharma Competitors ProQR Therapeutics Competitors Opthea Competitors Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:IOBT) was last updated on 12/18/2024 by MarketBeat.com Staff From Our PartnersThis drone stock is setting up to transform medical supply deliveryDrone stocks are on a tear, with certain symbols seeing gains as high as 300% over just a matter of weeks.The Tomorrow Investor | SponsoredUncover the Top Gold Stock of the Bull MarketGold Stocks Are Surging—Is West Red Lake Gold Mines Your Next Profit Play?Huge Alerts | SponsoredHealthcare Takes A Big Step Forward With The Help of A.I.To date, we've seen baseline AI models lay the groundwork. Tools like ChatGPT are useful, but they are still s...Wall Street Star | Sponsored Is Starlink Set For The Largest IPO In History?He turned PayPal from a tiny, off-the-radar startup… to a massive $64 billion giant. Then, he did it again ...Paradigm Press | SponsoredTrump’s Sending THIS Crypto Higher on PurposeDiscover the coin set to explode before 2025! Trump could trigger THIS crypto coin… Crypto 101 Media | Sponsored50-year Wall Street legend: “Sell this tech stock NOW”Something very strange is happening to U.S. stocks following President Trump's victory... And this could s...Chaikin Analytics | SponsoredSeeing is believing… Today, I want to share all the details with you… and show you how to leverage this incredible wealth-building ...Porter & Company | SponsoredURGENT: This Altcoin Opportunity Won’t Wait – Act NowIt’s here. This is the moment we’ve been waiting for. The next 3-6 months in crypto will be absolutely life...Crypto Swap Profits | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding IO Biotech, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share IO Biotech With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
